🇮🇳IN
Sign In
GL

GLENMARK

NSE

Glenmark Pharmaceuticals Ltd

₹2,166.60

-31.90(-1.45%)
FSI

Fundamental Strength Index

computed from the statements below↑ higher is better

Weights come from configuration, not from this page — each pillar links to the section below that explains it.

Income stmtHistory

Profitability

headline ratios

Growth

compounded, from filed annual results

Segment Results

₹ Cr

Working Capital & Efficiency

days · ROCE %

GLENMARK financial summary

For Mar 2026, Glenmark Pharmaceuticals Ltd reported revenue of ₹8,440 crore, which fell 8.5% from the previous year. Net profit was -₹201 crore, which fell 112.5% year on year, on an operating margin of 13%. Earnings per share came in at -₹7.12. Annual results are available for 14 financial years, from Mar 2013 to Mar 2026.

Revenue₹8,440 crore
Net profit-₹201 crore
Operating margin13%
EPS-₹7.12

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer